ALS clinical trials at Mass General Brigham
In addition to the HEALEY ALS Platform Trial, several ALS clinical trials and research studies at Mass General are enrolling participants. These studies hope to:
- Evaluate new medications and cell therapies.
- Create a library of biofluid samples for use in future research.
- Develop technology to help people control assistive devices without the use of their hands.
- Guide clinical recommendations to maximize physical functions such as neck support and exercise.
- Prevent disease in certain hereditary forms of ALS.
- Target programs and resources to improve quality of life.
- Test smartphone apps used for the collection of patient data.
- Develop new ways to diagnose and monitor ALS, such as new biomarkers.
“This is an exciting time to take part in clinical research and there are many more options than ever,” says Dr. Paganoni.
PREVAiLS: Pridopidine study for early, rapidly progressive ALS
In early 2026, a new Phase 3 clinical trial begins recruiting participants to test the drug pridopidine in people with early, rapidly progressive ALS. The trial, called PREVAiLS, emerges from previous research in the HEALEY ALS Platform Trial.
The PREVAiLS study aims to confirm the results of the HEALEY ALS trial in those with rapidly progressive ALS diagnosed in the past 18 months. “This study tests a much-needed new treatment option for ALS focused on therapeutic priorities—slowing of functional decline, maintaining speech, and prolonging survival,” says Dr. Paganoni, who is a PREVAiLS Steering Committee member and investigator.
In addition to the PREVAiLS study, an expanded access program offers pridopidine to people who aren’t eligible to participate in the clinical trial. The Sean M. Healey & AMG Center for Integrated ALS Care and Discovery at Mass General runs the program. Expanded access programs give patients access to critical treatments and contribute valuable efficacy and safety data to the research.
Access for All in ALS (ALL ALS)
The Accelerating Access to Critical Therapies for ALS Act of 2021 established a national clinical research consortium in 2023. ALL ALS is led by James Berry, MD, MPH, in collaboration with Suma Babu, MD, MPH, MBBS, and Dr. Paganoni, along with investigators at three other academic medical centers. The consortium collects and organizes samples and data from people with ALS and people at increased genetic risk for ALS.
“The goal of the consortium is to develop the largest data set and biosample repository from people living with ALS. This will lead to many discoveries,” says Dr. Paganoni.
BrainGate Neural Interface System
Leigh Hochberg, MD, PhD, director of the Center for Neurotechnology and Neurorecovery at Massachusetts General Hospital, is director of the BrainGate Consortium and clinical trials.
BrainGate is trying to determine if a device implanted in the brain can help people with ALS control assistive devices with thought. The technology is targeted to people who have lost the use of their limbs or their ability to speak, including those with neurologic diseases such as ALS and beyond.
In a recent clinical trial, BrainGate researchers tested an implantable brain-computer interface that helped a 45-year-old patient with ALS successfully communicate again. The interface “decoded” the patient’s brain signals as he attempted to speak and used artificial intelligence to create a computer-generated version of his own voice.
Healey ALS MyMatch
In 2025, the Healey & AMG Center launched the Healey ALS MyMatch program. Led by Suma Babu, MBBS, MPH, ALS MyMatch is a multisite, early-phase (Phase 1b/2a) clinical trial program in ALS.
To date, the program has received 17 applications from drug developers and has accepted nine. The first MyMatch clinical trial, ACACIA trial, was completed and announced results in September 2026. The second trial, BANYAN trial, is currently enrolling participants. Four additional trials have completed trial design and are pending regulatory approvals for initiating enrollment.
In the program, series of independent clinical trials of gene-targeted and an array of other investigational therapeutics are designed and conducted using custom trial designs to meet the scientific objectives of each trial. A common screening protocol allows for participants to screen once, undergo genetic and biomarker profiling, and that information is then used to match to the right trial in the program. By prioritizing high-quality biomarker-driven target engagement and dose-finding information in early-phase clinical trials, ALS MyMatch paves the way for efficient therapeutic development in ALS.
Data from successful ALS MyMatch trials will inform future late phase clinical trial design via the HEALEY ALS Platform Trial or a standalone Phase 2/3 trial.
Where do I find more information about clinical trials for ALS?
“This is the right time to engage with ALS research. Clinical trials and research studies can give people with ALS the best possible tools to fight the disease now. Your collaboration also will help develop more treatments in the future,” says Dr. Paganoni.
Start by talking to your doctor, who can offer guidance about the most appropriate research options for your circumstances. For more details about research opportunities and updates about treatment options at Mass General Brigham:
- Visit our ALS research page for a detailed list of current trials and studies and to apply.
- Register for ALS Link, a newsletter with clinical care information from ALS experts at the Healey & AMG Center for ALS and updates about the HEALEY ALS Platform Trial and other research.
- Register for ALS webinars for weekly discussions about the platform trial and other helpful topics.
Working together, the outlook for ALS treatment is hopeful, says Dr. Paganoni.
“We need to keep the momentum going, with more funding, more initiatives, and continued participation from the ALS patient community, so that we can make progress together.”